by heliosinc | 2025-08-12 23:20:47+00:00
Thanks for the feedback! Really appreciate it as we're early and continuing to build this out. Answers below:

1. the chat mode only has access to our evergreen pubmed embeddings so it's going to struggle with like conferences/events that are recent. We have the agent mode (toggle) that is made for accessing information like that via its expansive search capabilities. Here is an agent response for your query. How does this look in terms of its response/content quality?

2. Thanks for flagging pubmed.ai. I took a look and based on some early testing, it doesn't seem to be as good as our responses. Our prompting, pipeline, agentic workflows are crafted by scientists and doctors, reflecting the most common concerns of patients/consumers and most interesting use cases (e.g. chronic disease risk, drug/supplement interactions, supplement stack analysis, cancer risk, etc). Will continue to benchmark against this though.

3. We're trying to target general population (patients/health oriented consumers). I think this suggestion is spot on. We will work on releasing a new version that is more WebMD/consumer friendly in its language.

Agent response from OpenHealth (https://www.my-openhealth.com/):

Research Plan (this is the plan it executed) 1. Given the American Diabetes Association 2025 conference has not yet occurred, research the most recent American Diabetes Association (ADA) Standards of Medical Care in Diabetes (e.g., 2024 or latest available) for current and emerging treatment recommendations for Type 2 Diabetes. 2. Investigate key themes and emerging research presented at recent major diabetes conferences (e.g., ADA 2024, EASD) and in leading endocrinology journals that are likely to influence future ADA recommendations for Type 2 Diabetes treatment, focusing on novel drug classes, personalized medicine, and technology. 3. Analyze current guidelines and recent updates regarding the integration of comprehensive lifestyle interventions (dietary patterns, exercise, weight management), cardiovascular and renal protective strategies, and advanced glucose monitoring in Type 2 Diabetes management. 4. Search Reddit (e.g., r/diabetes, r/type2diabetes) and Twitter for discussions among patients and healthcare professionals regarding recent or anticipated shifts in Type 2 Diabetes treatment recommendations, real-world experiences with newer therapies, and common challenges or successes in implementing guideline changes. 5. Synthesizing final report - Combining all research findings into a comprehensive health report

References (21)

Your Question what are new treatment recommendations for type 2 diabetes from the American Diabetes Association 2025 conference?

Type 2 Diabetes Management Guide The American Diabetes Association (ADA) annually updates its "Standards of Care in Diabetes" to provide current clinical practice recommendations for diabetes care. While the ADA 2025 conference has not yet occurred, the "Standards of Care in Diabetes-2025" have been published as of January 1, 2025, outlining the latest evidence-based guidelines for managing Type 2 Diabetes (T2D) [1]. These standards are developed by an interprofessional expert committee to provide comprehensive guidance, including treatment goals and quality evaluation tools [1].

Current Evidence & Treatment Options The ADA 2025 Standards emphasize a patient-centered approach, integrating novel drug classes, personalized medicine, and advanced technology into T2D management [2].

Key Themes and Emerging Research Artificial Intelligence (AI) and Technology in Diabetes Management:

AI is increasingly explored for through advanced algorithms and predictive modeling, enhancing screening, diagnosis, therapeutic decision-making, and outcome prediction in T2D [3]. driven by AI, integrated with electronic health records (EHR), assist healthcare providers in analyzing patient data and setting therapeutic objectives [3]. AI and Machine Learning (ML) also play a crucial role in accelerating by analyzing extensive datasets and enhancing predictions, potentially reducing the time and costs associated with bringing new drugs to market [4]. Personalized Medicine Approaches:

Continued below...